Vaishali Pharma fixes record date for 1:1 bonus issue & 1:5 stock split, expects to continue strong growth momentum

Mumbai-headquartered Vaishali Pharma’s board has fixed October 15 as the record date for proposals to issue bonus share and split the company’s stock. The company will split its equity shares, having a nominal face value of Rs 10 each, into 5 equity shares of Rs 2 each, and issue bonus shares in the ratio of 1:1. 

Catering to semi-regulated and non-regulated markets across the world, the company had recently obtained 19 registrations across Southern Africa, West Africa, the Gulf region, Latin America, and the ASEAN region. These registrations are poised to contribute around Rs 10 crore to the company’s annual revenue. 

Backed by strong product portfolio and distribution network, the company had staged a robust financial performance for Q1 FY25. 

For the quarter ended June 30, the company’s sales increased by 34.70 per cent to Rs 18.08 crore. Its net profit rose 7.13 per cent to Rs 1.70 crore. 

“We are proud to inform our stakeholders that the company is making significant strides in its long-term growth strategy, delivering excellent operational and financial results. Consideration of stock split and bonus shares are in line with the company’s vision to reward the shareholders and earn their long-lasting trust and confidence,” said Atul Vasani, Chairman and Managing Director, Vaishali Pharma Ltd. 

“This move will not only reward our existing shareholders for their continued support but also increase the company's equity base, thereby enhancing liquidity. With a focus on growth and innovation, the company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector,” said Vasani. 

Established in 1989, Vaishali Pharma Limited specialises in the production and marketing of a diverse range of pharmaceutical products, including APIs, formulations, surgical products, veterinary supplements, herbal items, nutraceuticals, and oncology products. 

Its portfolio caters to both human and animal healthcare needs. 

The company has over 250 formulation brands marketed in multiple countries and a robust pipeline of around 250 dossiers. The company’s synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients. 

It is one of the fastest growing and most versatile company in the pharmaceutical industry. It has a strong presence in both the domestic and export markets and is currently supplying to all leading Indian and international companies.

With a vision “to be a well-recognised Indian MNC in the pharmaceuticals and healthcare industry”, the company continues to work on its mission to contribute substantially towards well-being and health of society by providing high quality products and services.

(This article is part of IndiaDotCom Pvt Ltd’s Consumer Connect Initiative, a paid publication programme. IDPL claims no editorial involvement and assumes no responsibility, liability or claims for any errors or omissions in the content of the article.)